Do you want to read an article? Please log in or register.
Characteristics and Clinical Outcomes of De Novo and Acquired Uncommon Compound EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer: A Brief Report
Lung Cancer
Related content
Lung Cancer
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
Eur J Cancer
Arriola E, Casarini I, Özgüroğlu M, Huang M, Takahashi T, Lai X, Goto K, Maneenil K, Lee KH, Cobo M, Valdiviezo N, Evans A, Bolanos A, Huang X, Lai R, Ramalingam SS
doi: 10.1016/j.ejca.2026.116744
Lung Cancer
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
Lancet Oncol
Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, García Campelo R, Jotte R, Berz D, Spira A, Pérol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L
doi: 10.1016/S1470-2045(26)00282-2
Lung Cancer
Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)
Nat Commun
Shen B, Wang C, Zhang L, Zhu Y, Zhang X, Wang X, Guo Z, Wang L, Wang X, Zhu L, Zhou Y, Liao D, Shi M
doi: 10.1038/s41467-026-68554-6
Lung Cancer
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial
Lung Cancer
Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL
doi: 10.1016/j.lungcan.2026.109385
Lung Cancer
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)
Lung Cancer
Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S
doi: 10.1016/j.lungcan.2025.108840
Lung Cancer
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
Lancet Oncol
Li Z, Hu J, Chen J, Yu Y, Meng X, Dong X, Hu Y, Ji Y, Liu H, Wang W, Ning F, Zhang Z, Liu C, Zhang Z, Wang Q, Zheng W, Wang H, Qu X, Chen Z, Fan S, Zhang X, Lu S
doi: 10.1016/S1470-2045(26)00090-2
Lung Cancer
Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer
Nat Commun
Zhou F, Su C, Liang W, Xu LD, Tao W, Qian J, Xu S, Liu D, Fan R, Zhang Y, Liu Y, Wu L, Fu X, Zhang X, Shen N, Ge D, Chen Q, Mao W, Xu L, Chen C, Hu B, Shao G, Hu J, Zhao J, Liu X, Liu Z, Wang Z, Xiao Z, Gong T, Lin W, Li X, Ye F, Liu Y, Ma H, Huang Y, Zhou J, Wang Z, Fu J, Ding L, Mao L, Chen W, He J, Zhou C
doi: 10.1038/s41467-026-76392-9
RECOMMENDED
Lung Cancer
Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
ESMO Open
Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV
doi: 10.1016/j.esmoop.2025.106031
Lung Cancer
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials
Lung Cancer
Zhou DD, Lord SJ, Lin FP, Cooper WA, Zaheed M, Simes RJ, John T, Lee CK
doi: 10.1016/j.lungcan.2025.108891